We are delighted to share that the SIOPEN High-Risk Neuroblastoma 2 trial is now officially open and ready to recruit at its first UK hospital, with more to follow soon.

In May 2020, we announced the award of £609, 762 in partnership with Solving Kids Cancer to open the UK sites of the SIOPEN High-Risk Neuroblastoma 2 trial. This latest European-wide study will look to answer important questions about the standard care protocols for children with high-risk neuroblastoma, and how they might be improved.